• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc. (Amendment)

    2/14/24 4:47:34 PM ET
    $MDGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MDGL alert in real time by email
    SC 13G/A 1 madrigal13ga1-12312024.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    (Rule 13d-102)
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2(b)
    (Amendment No. 1)1
     
    Madrigal Pharmaceuticals, Inc.
    (Name of Issuer)
    Common Stock, $0.0001 par value per share
    (Title of Class of Securities)
    558868105
    (CUSIP Number)
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
     ☐
    Rule 13d-1(b)
     
     ☒
    Rule 13d-1(c)
     
     ☐
    Rule 13d-1(d)
     
     

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


                                           
     
    1
     
    NAME OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    PAULSON & CO. INC.
     
     
    2
     
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
     
     
     
     
    (b) ☒
     
     
     
     
     
     
     
    3
     
    SEC USE ONLY
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    4
     
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
     
     
     
     
     
     
     
    DELAWARE
     
    NUMBER OF
     
    5
     
    SOLE VOTING POWER
     
    SHARES
     
     
     
     
     
    BENEFICIALLY
     
     
     
     
    1,105,741 (See Note 1 to Item 4 below)
     
    OWNED BY
     
    6
     
    SHARED VOTING POWER
     
    EACH
     
     
     
     
     
    REPORTING
     
     
     
     
    0
     
    PERSON WITH
     
    7
     
    SOLE DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    1,105,741 (See Note 1 to Item 4 below)
     
     
     
    8
     
    SHARED DISPOSITIVE POWER
     
     
     
     
     
     
     
     
     
     
     
     
    0
     
     
    9
     
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    1,105,741 (See Note 1 to Item 4 below)
     
     
    10
     
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐
     
     
     
     
     
     
     
     
     
     
     
     
    11
     
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
     
     
     
     
     
     
     
    5.6%
     
     
    12
     
    TYPE OF REPORTING PERSON
     
     
     
     
     
     
     
     
     
     
    IA
     
     



    Item 1(a).
    Name of Issuer:
     
    Madrigal Pharmaceuticals, Inc. 
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
     
    Four Tower Bridge
    200 Barr Harbor Drive, Suite 200
    West Conshohocken, PA 19428

    Item 2(a).
    Name of Persons Filing:

    Paulson & Co. Inc. (the “Reporting Person”)
    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    1133 Avenue of the Americas, New York, NY 10036
    Item 2(c).
    Citizenship:

    Delaware corporation
    Item 2(d).
    Title of Class of Securities:

    Common stock, $0.0001 par value per share (the “Common Stock”)
    Item 2(e).
    CUSIP Number:

    558868105
    Item 3.
    If this statement is filed pursuant to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    /x/
    Not Applicable
    (a)
    / /
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b)
    / /
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    / /
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)
    / /
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)
    / /
    Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E).*
    (f)
    / /
    Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F).
    (g)
    / /
    Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G).**
    (h)
    / /
    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)
    / /
    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3).
    (j)
    / /
    Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
    (k)
    / /
    Group, in accordance with Section 240.13d-1(b)(1)(ii)(J).
     

    Item 4.
    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer.

    (a)
    Amount beneficially owned: 1,105,741

    (b)
    Percent of class: 5.6%
    (c)            Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote: 1,105,741 (See Note 1)

    (ii)
    Shared power to vote or to direct the vote: 0

    (iii)
    Sole power to dispose or to direct the disposition of: 1,105,741 (See Note 1)

    (iv)
    Shared power to dispose or to direct the disposition of: 0
    The aggregate percentage of Common Stock reported owned by each person named herein is based upon 19,742,646 shares of Common Stock outstanding as of November 1, 2023, which is the total number of shares of Common Stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2023.
    Note 1: Paulson & Co. Inc. (“Paulson”) and its affiliates furnish investment advice to and manage onshore and offshore investment funds and separate managed accounts (such investment funds and accounts, the “Funds”).  In its role as investment advisor, or manager, Paulson possesses voting and/or investment power over the securities of the Issuer described in this schedule that are owned by the Funds.  All securities reported in this schedule are owned by the Funds.  Paulson disclaims beneficial ownership of such securities.
    Item 5.
    Ownership of Five Percent or Less of a Class.

    Not applicable.
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    All securities reported in this schedule are owned by Paulson's advisory clients, none of which to Paulson's knowledge owns more than 5% of the class. Paulson itself disclaims beneficial ownership of all such securities.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group.

    Not applicable.

    Item 9.
    Notice of Dissolution of Group.

    Not Applicable.

    Item 10.
    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURES
    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information with respect to it or him set forth in this statement is true, complete and correct.
    Dated: February 14, 2024
    PAULSON & CO. INC.
    By: /s/ Stuart L. Merzer 
          Stuart L. Merzer,
          General Counsel & Chief Compliance Officer
    Get the next $MDGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDGL

    DatePrice TargetRatingAnalyst
    2/28/2025$236.00 → $422.00Neutral → Buy
    B. Riley Securities
    2/27/2025$400.00 → $405.00Buy
    H.C. Wainwright
    6/28/2024Neutral
    Cantor Fitzgerald
    6/11/2024$382.00Outperform
    Wolfe Research
    4/22/2024$150.00Underperform
    BofA Securities
    3/15/2024$155.00 → $270.00Sell → Neutral
    B. Riley Securities
    3/6/2024$382.00Buy
    Citigroup
    2/26/2024$155.00Neutral → Sell
    B. Riley Securities
    More analyst ratings

    $MDGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

      CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. EDT. The presentation will be webcast live and may be accessed here or by visiting Madrigal's Investor Relations Events and Presentations page. A replay of the webcast will be available after the event. About MadrigalMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Ma

      6/2/25 8:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis

      Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk categories by year twoPatients achieved a mean 6.7 kPa reduction in liver stiffness, which was statistically significant compared to baseline CONSHOHOCKEN, Pa., May 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced positive two-year results from the open-label compensated MA

      5/10/25 7:15:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

      First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marketable securities of $848.1 million at March 31, 2025Company to host conference call today, May 1, 2025, at 8 a.m. EDT CONSHOHOCKEN, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.

      5/1/25 7:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Madrigal Pharmaceuticals upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Madrigal Pharmaceuticals from Neutral to Buy and set a new price target of $422.00 from $236.00 previously

      2/28/25 8:25:11 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Madrigal Pharmaceuticals with a new price target

      H.C. Wainwright reiterated coverage of Madrigal Pharmaceuticals with a rating of Buy and set a new price target of $405.00 from $400.00 previously

      2/27/25 6:40:20 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Madrigal Pharmaceuticals

      Cantor Fitzgerald initiated coverage of Madrigal Pharmaceuticals with a rating of Neutral

      6/28/24 7:43:43 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Financials

    Live finance-specific insights

    See more
    • Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates

      First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marketable securities of $848.1 million at March 31, 2025Company to host conference call today, May 1, 2025, at 8 a.m. EDT CONSHOHOCKEN, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.

      5/1/25 7:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

      Patients achieved a mean 6.7 kPa reduction in liver stiffness as measured by vibration-controlled transient elastography (VCTE); this represents the largest reduction in liver stiffness reported in a compensated MASH cirrhosis patient population 51% of patients achieved a ≥25% reduction in liver stiffness; a reduction of this magnitude has been associated with reduced progression to end-stage liver diseaseCompany to review topline data during its fourth-quarter and full-year 2024 financial results conference call today, February 26, 2025, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused

      2/26/25 6:30:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

      Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered lives require biopsy Completed enrollment of clinical outcomes study of Rezdiffra in patients with compensated NASH/MASH cirrhosisReports cash, cash equivalents, restricted cash and marketable securities of $1.0 billion at September 30, 2024Company to host conference call today, October 31, 2024, at 8 a.m. EDT CONSHOHOCKEN, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic stea

      10/31/24 7:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

      Fred Craves, Ph.D. to retire from Madrigal's Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn ("Jackie") Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from the Board in July 2025. Julian Baker, Chairman of the Board of Directors, stated, "I am delighted to welcome Jackie Fouse to Madrigal. Jackie is an accomplished biotech executive who brings more than 30 years of healthcare industry and finance experience

      3/11/25 8:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

      CONSHOHOCKEN, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today announced the appointment of Michael R. Charlton, M.B.B.S., F.R.C.P., as Senior Vice President, Clinical Development, effective October 1, 2024. Becky Taub, M.D., Chief Medical Officer and President of Research & Development of Madrigal, stated, "I am thrilled to have Dr. Charlton joining the Madrigal team; his deep experience as a researcher and clinician treating patients with NASH will bring powerful new insights and ca

      10/1/24 8:00:00 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

      CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Shannon is an outstanding leader who brings a wealth of expertise to her new role as General Counsel. She joined the Madrigal team in 2024 as Chief Compliance Officer and played an instrumental role guiding the company through a period of rapid growth. I feel privileged to be working with Shannon and the other members of our leader

      8/2/24 7:00:21 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Baker Bros. Advisors Lp bought $22,516,577 worth of shares (101,792 units at $221.20) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      12/14/23 6:10:59 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baker Bros. Advisors Lp bought $7,548,616 worth of shares (34,578 units at $218.31) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      12/14/23 6:09:05 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baker Bros. Advisors Lp bought $12,128,340 worth of shares (64,350 units at $188.47) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      11/21/23 6:15:19 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    SEC Filings

    See more
    • SEC Form 10-Q filed by Madrigal Pharmaceuticals Inc.

      10-Q - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)

      5/1/25 8:53:57 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Madrigal Pharmaceuticals Inc.

      8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)

      5/1/25 7:02:50 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Madrigal Pharmaceuticals Inc.

      DEFA14A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)

      4/29/25 4:21:46 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Soergel David was granted 7,545 shares (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      5/16/25 6:23:51 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Soergel David

      3 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      4/24/25 5:03:13 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Craves Fred B exercised 15,470 shares at a strike of $82.90 and sold $5,082,480 worth of shares (15,470 units at $328.54) (SEC Form 4)

      4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)

      3/14/25 4:25:06 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc.

      SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

      11/14/24 5:18:50 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Madrigal Pharmaceuticals Inc.

      SC 13G - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

      11/14/24 6:30:21 AM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Madrigal Pharmaceuticals Inc. (Amendment)

      SC 13D/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)

      3/25/24 4:28:21 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MDGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

      Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity

      3/14/24 3:35:50 PM ET
      $MDGL
      Biotechnology: Pharmaceutical Preparations
      Health Care